{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:59:52Z","timestamp":1790398792776,"version":"4.1.0"},"reference-count":15,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2026]]},"DOI":"10.5582\/ddt.2026.01064","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:10:51Z","timestamp":1790287851000},"source":"Crossref","is-referenced-by-count":0,"title":["Bepirovirsen: The first antisense oligonucleotide approved to achieve a functional cure for chronic hepatitis B"],"prefix":"10.5582","author":[{"given":"Yueyi","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. You H, Wang F, Li T, Xu X, Sun Y, Nan Y, Wang G, Hou J, Duan Z, Wei L, Jia J, Zhuang H, Chinese Society of Hepatology CMA, Chinese Society of Infectious Diseases CMA. Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022). J Clin Transl Hepatol. 2023; 11:1425-1442.","DOI":"10.14218\/JCTH.2023.00320"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Dai Y, Bai S, Yang P, Wang H, Li X, Shen F, Wang K. Elevated alpha-fetoprotein affects the long-term prognosis after hepatectomy in patients with hepatitis B-related intrahepatic cholangiocarcinoma. Biosci Trends. 2026; 20:105-121.","DOI":"10.5582\/bst.2025.01327"},{"key":"3","unstructured":"3. World Health Organization. Chronic hepatitis B. <i>https:\/\/www.who.int\/zh\/news-room\/fact-sheets\/detail\/hepatitis-b<\/i> (Accessed September 1, 2026)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hui Z, Yu W, Fuzhen W, <i>et al.<\/i> New progress in HBV control and the cascade of health care for people living with HBV in China: evidence from the fourth national serological survey, 2020. Lancet Reg Health West Pac. 2024; 51:101193.","DOI":"10.1016\/j.lanwpc.2024.101193"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hosaka T, Hikita H, Tahata Y, <i>et al.<\/i> On-treatment viral factors affect subsequent hepatitis B surface antigen seroclearance in patients treated with nucleos(t)ide analogs for &gt; 10 years. J Gastroenterol. 2026; 61:990-1002.","DOI":"10.1007\/s00535-026-02415-3"},{"key":"6","unstructured":"6. The Japanese Ministry of Health, Labour and Welfare. Regarding Pharmaceuticals Approved as New Drugs. <i>https:\/\/www.mhlw.go.jp\/hourei\/doc\/tsuchi\/T260824I0010.pdf<\/i> (accessed September 2, 2026). (In Japanese)"},{"key":"7","unstructured":"7. HIBSAGO Syringes for S.C. injection. <i>https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/340278_62504B0G1021_1_01?utm_source<\/i> (Accessed September 4, 2026). (In Japanese)"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Han K, Theodore D, McMullen G, Swayze E, McCaleb M, Billioud G, Wieland S, Hood S, Paff M, Bennett CF, Kwoh TJ. Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsen in Hepatitis B Virus-Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses. Clin Pharmacol Drug Dev. 2022; 11:1191-1202.","DOI":"10.1002\/cpdd.1154"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Delahaye JL, You S, Fu K, <i>et al<\/i>. Bepirovirsen induces innate immune proteins independent of HBV. Hepatol Int. 2026. doi: 10.1007\/s12072-026-11134-z.","DOI":"10.1007\/s12072-026-11134-z"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Ermler ME, Delahaye JL, Jordan W, <i>et al.<\/i> Bepirovirsen induces innate immune activation in the liver potentially through TLR8 signaling. JHEP Rep. 2026; 8:101923.","DOI":"10.1016\/j.jhepr.2026.101923"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hou J, Lim SG, Buti M, <i>et al<\/i>. Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection. N Engl J Med. 2026; 394:2395-2406.","DOI":"10.1056\/NEJMoa2515131"},{"key":"12","unstructured":"12. ClinicalTrials.gov. Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1). <i>https:\/\/clinicaltrials.gov\/study\/NCT05630807<\/i> (accessed September 3, 2026)."},{"key":"13","unstructured":"13. ClinicalTrials.gov. Long-term follow-up study to evaluate durability of response in chronic hepatitis B (B-Sure). Identifier: NCT04954859. <i>https:\/\/clinicaltrials.gov\/study\/NCT04954859<\/i> (accessed September 3, 2026)."},{"key":"14","unstructured":"14. ClinicalTrials.gov. Study of bepirovirsen in participants living with HIV and chronic HBV infection (B-Focus). Identifier: NCT06497504. <i>https:\/\/clinicaltrials.gov\/study\/NCT06497504<\/i> (accessed September 3, 2026)."},{"key":"15","unstructured":"15. ClinicalTrials.gov. Study of sequential treatment with daplusiran\/tomligisiran followed by bepirovirsen in participants living with chronic hepatitis B (B-United). Identifier: NCT06537414. <i>https:\/\/clinicaltrials.gov\/study\/NCT06537414<\/i> (accessed September 3, 2026)."}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/advpub\/0\/advpub_2026.01064\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:29:58Z","timestamp":1790396998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/advpub\/0\/advpub_2026.01064\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":15,"URL":"https:\/\/doi.org\/10.5582\/ddt.2026.01064","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"2026.01064"}}